Jianxing Fund

  • Shenzhen TargetRx secures RMB150m Series A

    Innovative drug research and development company Shenzhen TargetRx recently announced that the company has raised 150 million yuan in a Series A financing round.
    This round of investment was led by CCB International’s Jianxing Fund, with participation from Oriental Fortune Capital, Tsing-yuan Capital, and existing investor Shenzhen Capital Group and others.